Abstract
Complications of CHB including cirrhosis result in nearly 1 million deaths annually. Renal dysfunction is common in decompensated CHB cirrhosis and is associated with high mortality. Nucleot(s)ide treatment improves liver function and survival. Renal dysfunction can reduce clearance of nucleot(s)ides increasing drug-associated toxicities resulting with high mortality. Recently, study on decompensated CHB patients showed significantly improvement of GFR for those receiving telbivudine in comparison to patients under lamivudine. We assessed GFR in compensated CHB patients included in several pivotal telbivudine (LDT) trials. GFR was performed at baseline (BL), Week 52 (W52), W104 and W208 by MDRD (Modification of Diet in Renal Disease): LDT vs. lamivudine (LAM) (n=1370); LDT for 4-years (n=1869); 2 years LDT vs. LAM in decompensated patients (n=232); LDT roadmap study with tenofovir (TDF) add-on (n=105).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
